Member Info for sadoldgit

That is a fact.

Phase1a healthy volunteers

Phase 1b in Psoriasis patients.

We have completed phase1a

As of this time we have not entered phase1b.

If you read the link you should be able to understand and realise that.

Regards

You are 100% correct HbD.

I will add that the data will be subject to analysis.

It is not huge data as in treating an indication so ought not take long, maybe 2 to 3 weeks unless of course a waiting list.

Judging by the change in management we should here very soon of developments.

These are not the results that HbD has provided the link to. It is the outline of the purpose and criteria of the phase 1a trial along with the oh so important 21/6/24 and update 14/7/24

It is to inform us that the trial of single and multiple ascending doses have been completed along with the trial data results.

Await an incoming RNS for data results this week

I would hazard a guess Tuesday onwards.

Confident we will see great results and of course now the unblinded results as a comparison.

Not a question of if we are just good, it is a matter of just how good.

Regards to all.

HbD l have always found your posts fact based with good opinion and positive.

Open to debate in all areas.

We know what the option are available but we don't know which one Sareum will take.

Greater value to be had as a phase 2 candidate albeit being low numbers as proof of concept.

A question l would ask is where exactly are they going to carry this trial out?

Are they sticking with Oz?

The CRO in down under carrying out phase 1a are worthy of praise.

Not sure l would suggest the same over here.

Regards

Good morning Potnak.

If the science and sentiment are not linked then tell me what would happen or have happened should 1801 results been disastrous?

As for sentiment with regards to sufficient funding that is very plausible.

News needs to be relayed soon.

We are looking for non dilutive funding is not enough.

Equity release is out of the window, so either comes from investment and the only options here are onlicence or partnership.

Both will have an effect on share price.

As a scenario in a partnership company a agrees to fund phase 2 trials. What percentage would this company want with regards to ownership or revenue?

For a vompany to become involved in needs to know 1801 in its entirety.

That is safety in depth and efficacy and both are interrelated.

Efficacy can be limited by the amount of dosing leading to toxicity and adverse events.

That happens in many compounds and is a main function of drug failure.

Efficacy in an indication can be achieved by on vivo Studies that they will work. However the amounts of compound administered is many times higher than that which would be considered a therapeutic dosing level in the human being.

That is where we sit. We have not progressed to the maximum envisaged dose of 1000mg per day.

Psoriasis not a problem as l see it.

Other Indications will require higher dosing.

That is where we sit at the moment

Any form of, or degree of funding will indicate the confidence that a 3rd party has.

That will rely on the total amount of preclinical data, binded and unblinded data.

I am of the opinion that there are on going discussions with interested party or parties to which the are giving a low ball offer on informal discussions.

Likely we are not progressing and Tim now sidestepped as Parker in that temporary position.

How much a CEO going to be Paid?

Not going to get out of bed for less than 500k per year plus share options if he has any credibility.

So many loose ends at the moment that need tidying up.

Regards

Not sure if the SP would stagnate if and when a phase 2 was started.

The reason being updates being released with progress of compound.

Effectively 2 timescales.

12 weeks and 16 weeks.

The objective would be to reach a PASI score of 75 in 12 weeks and a further summary at 16 weeks as to a comparison with Deucravacitinib.

This of course would be with regards to efficacy and with relatively low numbers a proof of concept.

Results would need to be good.

Unblinded data carries a high degree of sensitive information and this information must be protected.

Who wants to see it and for what purpose?

Time consuming too.

Regards

relevance of below excerpt:-

upadacitinib jak1 selective.

tofacitinib jak1 and jak 3 selective. it also inhibits jak2

a question here

jak1 will heterodimerise with jak 2 and jak3

if we take as an example that all of the jak 1 heterodimerises with jak3, then that will leave jak 2 to ****dimerise with itself.

the downside of this of course is ****dimerisatuon of jak 2 will lead to epo a serious adverse event creator.

oursdc1801 is tyk2 selective over jak1.

the jak1 is selective over jaks 2 and 3.

tyk 2 can hetrodomerise with jak2 to benefit of il12 and il23 which is of benefit in psoriasis now on the process of validation with trials of ropsacitinib a tyk2 jak 2 inhibitor.

deucravacitinib being the allosteric tyk2 inhibitor that it is cannot ****dimerise with jak3.

it failed to meet its endpoints.

now tofacitinib is getting a tad long in the tooth as was granted nda approval on 2012 for uc.

you can certainly see that at some stage more effective and definitely a safer compound profile will knock tofacitinib off its perch.

the knock on effect is a drastic reduction for the owners that commercialise it.

results: a total of 155 patients initiated upadacitinib (n = 81; 30% prior tofacitinib exposure) or tofacitinib (n = 74; 0% prior upadacitinib exposure). after inverse probability of treatment-weighted logistic regression, upadacitinib was associated with significantly higher odds of sfcr (odds ratio 3.01, 95% confidence interval 1.39-6.55) vs tofacitinib. there were no differences for endoscopic response/remission.

discussion: upadacitinib was more effective at achieving sfcr in uc at 52 weeks vs tofacitinib.

the question now remains is just how much of a threat 1801 poses to tofacitinib and indeed upadacitinib?

pharmas that want this type of inhibitor will want it hor nothing.

the owners of tofacitinib and upadacitinib will not want the competition from better performing inhibitors.

Morning Potters.

By the very nature of being in Phase 2 carries more weight than remaining in Phase 1 along with greater value.

Can progress from Phase 2a to Phase 2b.

Now Should Sareum go the 1b route it sound then have to go Phase 2 trial which would mean large patient numbers of at least 100 most likely closer to 200.

Interesting spread pattern over the last few days,

Great Post thT Lsesar. Suggest you give mystic Meg a tinkle as l reckon got more idea than you.

Yes Rebster408, the grim reaper.

What is the intent of his posts if we do not know already.?

Regards

As Parker has taken the roll of CEO as an interim position, then why look for a CEO to replace him?

Unless they have someone in line or an external influence does it don't make sense.

Agree here with num4. However with regard to last paragraph.

The market took it positively.

Of course there will be people external to Sareum that will know what is in the process of going on.

Decravacitinib was 4 billion up front payment.

Albeit it was at the end of phase2b whilst we sit at end of phase 1a.

The primary value was attained on the safety aspects ie no associated black box warnings .

However as we know it failed to meet its end points in UC.

Extremely difficult to ascertain a realistic value at this stage.

However it may happen, 1801 has to progress to phase 2 trials.

Goid evening Num4,

They cannot announce a deal in progress if that were the case just as Sareum cannot announce who they are in discussions with.

Clearly l believe that Tim has been persuaded to stand down as prerequisite for further developments.

All will unfold very soon.

For the 1801 to complete by year end they need get their skates on.

So l would suggest something imminent due.

Still of the opinion more than one interested party.

Regards

Good evening Celtic007

A link below regarding hostile take overs.

I am not saying this is the case in exactness but certain aspects come into play.

https://www.investopedia.com/ask/answers/042815/what-are-some-prominent-examples-hostile-takeovers.asp

Sanofi acquisition of relevance here.

Albeit we most certainly are not looking at 20 billion.

We have kicked out PH and a few weeks later a management reshuffle.

By all means share your views, it don't matter a monkeys toss to me if your spelling or grammar is not 100% correct as is how you think that matters.

I would say we have had low ball offers, bound to happen.

SP suppressed even on positive news.

Are the HNWI's in any way connected?

Parker a good communicator but not have a great deal of trust in him.

Regards

I agree there 100% Aber.

It is unusual for a CEO to be repositioned without the announcement of who the next CEO will be.

https://www.linkedin.com/pulse/appointing-new-ceo-what-should-board-directors-consider-

xtvbf#:~:text=When%20boards%20of%20directors%20are,vision%2C%20values%2C%20and%20culture.

I would hazard a guess that there are informal talks concluding.

Look at the debacle with MHRA delay and costs.

They approach a CRO in Oz and within a few weeks we are in phase1 trials.

That is their area of expertise. Now likewise as we stand we have a very poor rudder.

Lack of communication or poor communication has been a result of poor CEO responsibilities.

We may have more than 1 interested party.

For a company to invest it will want its investment looked after.

No poor fund raises.

It is therefore very conceivable that a company is willing to invest but requires changes at management level to protect its investment.

A takeover of the company cannot be ruled out.

As l see it, the value of 1802 is potentially far greater than 1801.

The company ie Sareum would become a subsidiary.

I cannot see Tim standing down if it were an on licence, there looks to be more at play here.

Of course if an offer is made and has to be voted on, there are many who have come on board at a low SP.

Any other opinions as to why the management have been reshuffled?

If it is not either impending buyout or significant investment then what precisely would be the reason for management change?

Regards

Interesting opinion there Trader Matt.

For Tim ro step aside and not announce a CEO reeks of a deal of somesorts being struck.

It may well be take over time mainly for our Tyk2 Jak1 inhibitors.

I would hazard a guess that Tim good on the science but lacks business negotiating skills.

Good news.

Between 40 and 100k shares traded shown as sold within a couple of minutes. Several times during the day.

Strikes me as odd

While such schemes rely primarily on promotion or factual misstatements they are often supplemented by illegal trading tactics designed to deceive.

One common means is order spoofing, which involves the placing of numerous buy or sell orders designed to move the price of the stock, then canceling them once other traders have moved their own bids or asks accordingly.

3

Order spoofing has tempted staff at large Wall Street firms alongside shady daytraders, and can take place in the bond and metals markets as well as in the stock market.

Goof afternoon Potnak.

'Enter the TYK2, or tyrosine kinase 2 protein. Though part of the broader JAK family, TYK2 is viewed as a potentially safer target by scientists and drugmakers. That thinking was reinforced in September, when the Food and Drug Administration approved Bristol Myers Squibb’s Sotyktu for moderate-to-severe psoriasis without the safety warnings that have limited its JAK-blocking competitors.'

Now SOTYKTU had no safety concerns and a moderate efficacy in Psoriasis.

It failed to meet its end points in UC with the placebo performing better.

It was sold up front from Nimbus Therapeutics at a 4 billion dollar up front and 2 billion in milestone payments on sales.

It had no safety concerns. Wow a SMKI with no safety concern.

Was jumped on by Takeda.

They were at phase 2 trial admittedly.

However way we look at it, it still comes down to finalised data reports ie confirmation.

All we know is an expectation to recieve in Q3.

What is important to remember is these results will give the effects of the drug on the body.

No idea how long after taking the last dose but not think less than a month.

If the results are half decent would place them above Baricitinib. That has Bb warning.

The deal is not the done thing until it is done.

However there will be people outside of Sareum that will know before any of us here find out.

Regards